Short-term treatment of moderate to severe pain. It can also be used for pre-and post-operative anesthesia.
Composition:
1 ml of solution contains 10 mg of nalbuphine hydrochloride.
Action:
Contraindications:
Hypersensitivity to the active substance or any of the excipients. Severe kidney problems. Hepatic dysfunction. Simultaneous treatment with p-agonistic opioids, e.g. morphine and fentanyl.
Precautions:
Pregnancy and lactation:
Pregnant women should be treated with nalbuphine if the expected benefit to the mother outweighs the possible risk to the fetus. As with other opioids, long-term use by the mother, especially at the end of pregnancy, may cause withdrawal syndrome in the newborn, independent of the dose. As with all opioids, the efficacy and safety of nalbuphine hydrochloride during preterm delivery has not been studied. If the nalbuphine is given to the mother immediately before or during delivery, it should be monitored for neonatal depression, apnea, bradycardia or arrhythmias. Nalbuprea is excreted in human milk. Breast-feeding should be discontinued for 24 hours after nalbufin treatment.
Side effects:
Common: vomiting, nausea. Very rare: pain at the injection site, redness, urticaria, respiratory depression in newborns, delayed cardiovascular development in newborns. Nalbufin may cause some withdrawal symptoms if used in patients who use opioids in excessive amounts. If nalbuphine is used during labor, it may increase respiratory depression and / or delayed cardiovascular development in newborns with adverse consequences. In such cases, naloxone hydrochloride must be available as an antidote.
Dosage:
Intravenously, intramuscularly or subcutaneously. Adults: 10-20 mg most often for patients with mc. 70 kg, corresponding to a dose of 0.1-0.3 mg / kg. This dose may be administered intravenously, intramuscularly or subcutaneously and may be repeated after 3-6 h if necessary. The maximum single dose may not exceed 20 mg. Dosage must be adapted to the severity of pain and the general condition of the patient. Children and adolescents: most often 0.1-0.2 mg / kg This dose may be administered intravenously, intramuscularly or subcutaneously, intramuscular and subcutaneous administration can be painful and children should be avoided. The dose may be repeated after 3-6 h if necessary. The maximum single dose is 0.2 mg / kg. There is insufficient data on the treatment of children under 18 months old.Special groups of patients. Elderly patients are advised to start with the lowest dose of nalbuphine. Patients with moderate or mild renal dysfunction may show abnormal reactions at standard doses, and caution should be used in these patients. The preparation is not suitable for long-term treatment.
(C)
